Építés alatt – nem éles oldal
Belépés
Befejeződött2. fázis

Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)

A legfontosabb adatok

Ki végzi
Institute of Hematology & Blood Diseases Hospital, China
Hol
Kína1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Fázis
2. fázis
Résztvevők
17 fő vett részt
Kezdés
2024. ápr. 17.
Befejezés
2025. márc. 6.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Lusutrombopag Oral Tablet
A regiszteradat frissítve
2025. december 19.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 23 feltétel megnézéseKevesebb

Ki vehet részt

  • Males and females ≥18 years of age
  • Subjects>60 years must have had a diagnostic bone marrow aspiration in the last 3 years or responded to treatment (platelet count ≥50 x 10\^9/L)
  • Participants diagnosed with primary persistent/chronic ITP (greater than or equal to 3 months duration) and an average of two platelet count less than 30 x 10\^9/L. Conditions which may cause thrombocytopenia other than ITP should be ruled out, including but not limited to systemic lupus erythematosus (SLE),aplastic anemia (AA), and myelodysplastic syndromes (MDS)
  • Relapsed persistent or chronic ITP status, with or without prior splenectomy. Participants who previously received one or more ITP therapies
  • Subjects receiving rescue therapy (including but not limited to corticosteroids, immunoglobulins and immunosuppressant) must have completed these therapies for at least 1 week or failed within 1 week prior to dosing on the first day (Visit 1)
  • Subjects receiving stable dosages of cyclosporine A, mycophenolate mofetil, azathioprine, or danazol are allowed, but must be receiving a dose that has been stable for at least 4 weeks prior to dosing on the first day (Visit 1)
  • Subjects receiving Chinese herbal medicine must be stopped 1 weeks prior to dosing on the first day (Visit 1), and Chinese herbal medicine is not allowed during the study
  • Subjects receiving steroid therapy must be on a stable dose for at least 2 weeks prior to screening (same milligram amount ± 10%; and ≤20 mg of equivalent dose of prednisone)
  • Two consecutive mean platelet count < 30×10\^9/(a single platelet count of< 35×10\^9/L is allowed) during screening if subjects were not receiving steroids, or two consecutive mean platelet count < 50×10\^9/ if they were receiving steroids. Two Platelet counts must be measured at an interval of greater than 2 days and less than 14 days,and the second platelet count must be measured within 96 hours of day1(Visit 1)
  • Prothrombin time (PT) and activated partial thromboplastin time (APTT) within 20% of the upper limit of normal (ULN) at Screening or PT did not exceed normal value by ±3s and APTT by ±10s. No other history of coagulation state except ITP
  • A complete blood count within the reference range ,including count of white blood cell (WBC) differential not indicative of a disorder other than ITP, with the following exceptions: a) Hemoglobin: participants with hemoglobin levels between 10 g/dL (100 g/L) and the lower limit of normal (LLN) are eligible for inclusion; participants with anemia(hemoglobin levels <10g/dl ) clearly attributable to ITP (excessive blood loss) are also eligible for inclusion; b) Absolute neutrophil count (ANC) greater than or equal to 1.5x10\^9/L (elevated WBC/ANC due to corticosteroid treatment is acceptable)
  • All subjects must agree to take progestin or barrier contraception: patients with potential fertility (excluding hysterectomy, bilateral salpingectomy, bilateral tubal ligation or postmenopausal women for more than one year; Men with bilateral vasectomy) must take effective contraceptive measures at least 2 weeks before taking the study drug for the first time, throughout the study and within 28 days after the end of the study (or early termination of the study); Women with potential fertility must have a negative pregnancy test during the screening period and on the 0th day of the trial
  • A signed and dated written consent obtained prior to the performance of Screening procedures

Ki nem vehet részt

  • Females who were pregnant or lactating, or receiving other hormone/chemical contraceptives
  • Subjects unresponsive to previous TPO mimetics/agonists
  • Exposure to an investigative medication within 4 weeks prior to the initial Screening Visit or Use of the following drugs or treatment prior to Visit 1 (Day 1):; Within 12 weeks - alemtuzumab, multi-drug systemic chemotherapy, stem cell therapy; Within 12weeks - rituximab
  • History of clinically significant cardiovascular or thromboembolic disease within 26 weeks prior to Initial screening
  • Splenectomy within 4 weeks prior to Initial Screening
  • History of inherited or acquired, clinically important hemorrhagic clotting disorder
  • Laboratory abnormalities; Hemoglobin <10.0 g/dL for men or women, not clearly related to ITP; Absolute neutrophil count < 1000/mm3; Abnormal peripheral blood smear with evidence of fibrosis confirmed by bone marrow biopsy; Total bilirubin > 1.5 x ULN; Alanine aminotransferase (ALT) > 1.5 x ULN; Aspartate aminotransferase (AST) > 1.5 x ULN; Creatinine > 1.5 x ULN; Human immunodeficiency virus positive; Hepatitis A Immunoglobulin M(IgM) antibody positive, hepatitis B surface antigen positive and HBV DNA ≥1000IU/ml or hepatitis C antibody positive,with a history of acute hepatitis, cirrhosis, portal hypertension or chronic active hepatitis; Thyroid stimulating hormone (TSH) > 1.5 x ULN; or; Free thyroxine (T4) > 1.5 x ULN
  • Exposure to previous thrombopoietin (TPO) mimetics/agonists (e.g. romiplostim, recombinant human thrombopoietin (rhTPO), avatrombopag, eltrombopag and herombopag) within 4 weeks prior to initial screening.In addition, participants are allowed to be enrolled at the discretion of the investigator when platelet counts are below 30 x 10\^9/L within the 4 weeks after withdrawal of thrombopoietin (TPO) mimetics/agonists
  • Patients with potential fertility refused to take contraceptive methods
  • Other abnormalities except ITP or situations that investigators deem inappropriate to participate in this study

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This exploratory study is to investigate the efficacy, safety and tolerability of Lusutrombopag in the treatment of primary immune thrombocytopenia in Chinese patients who have failed first-line therapy

A vizsgálat csoportja

  • LusutrombopagA vizsgált kezelés

    Participants receive lusutrombopag 3 mg administered orally once a day for up to 4 weeks and titrated to a maximum dose of 6 mg during week 5 and week12 based on the platelet count (PLT)

    Kezelés: Lusutrombopag Oral Tablet

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
An Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Lusutrombopag in Chinese Adults With Persistent or Chronic Immune Thrombocytopenia
A regiszteradat frissítve
2025. december 19.